Genmab A/S announced new data from cohort B2 of the Phase 1/2 RAINFOL-01 trial, evaluating rinatabart sesutecan (Rina-S) in heavily pre-treated advanced endometrial cancer (EC) patients. With a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m² every 3 weeks resulted in a 50.0 percent confirmed objective response rate (ORR), including two complete responses (CR).
Anti-tumor activity was also observed in patients treated with Rina-S 120 mg/m² every 3 weeks, which yielded a 47.1 percent confirmed ORR. The median duration of response (mDOR) was not reached in either cohort, indicating sustained benefits.
Importantly, no signals of ocular toxicities, neuropathy, or Interstitial Lung Disease (ILD) were observed, which are common adverse events associated with other antibody-drug conjugates. These encouraging early signals support further development of Rina-S as a potential therapy for advanced and recurrent endometrial cancer, an area with limited treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.